^
    Back
    Association details:
    Biomarker:ARID1A mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ther Adv Med Oncol
    Title:

    Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy

    Published date:
    12/17/2022
    Excerpt:
    Herein, the pTMB and genetic alterations were investigated as predictive biomarkers for anti-PD-1 monotherapy outcome in metastatic non-small cell lung cancer (NSCLC)....Patients with ARID1A alteration (p = 0.007) had higher CBR compared with the wild type.
    DOI:
    https://doi.org/10.1177/17588359221141761